Enspryng 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0008 
Minor change in labelling or package leaflet not 
17/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10944
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202205 
satralizumab 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
PSUSA/10944
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202111 
satralizumab 
IB/0003/G 
This was an application for a group of variations. 
24/02/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0002 
B.I.a.1.z - Change in the manufacturer of AS or of a 
11/08/2021 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0001 
B.II.e.5.a.2 - Change in pack size of the finished 
26/07/2021 
30/06/2022 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
